The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis

Forced vital capacity (FVC) is a key measure of disease severity in patients with idiopathic pulmonary fibrosis (IPF) and is an important clinical trial endpoint. We hypothesize that reversible airflow limitation co-exists in a subgroup of patients with IPF, and that bronchodilator use will improve the performance characteristics of FVC.

Source: Respiratory Medicine CME - June 24, 2015 Category: Respiratory Medicine Authors: Deborah Assayag, Eric Vittinghoff, Christopher J. Ryerson, Elisabetta Cocconcelli, Roberto Tonelli, Xiaowen Hu, Brett M. Elicker, Jeffrey A. Golden, Kirk D. Jones, Talmadge E. King, Laura L. Koth, Joyce S. Lee, Brett Ley, Anthony K. Shum, Paul J. Wolters, Source Type: research